Drug Trial Radar · NCT02216227
Checklist to Prevent MRSA Surgical Site Infections
Last checked: Nov 19, 2026Latest source record: Mar 31, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
23,005
Actual
Start
Apr 1, 2014
Primary completion
Feb 28, 2021
Study completion Feb 28, 2021
Sponsor
- Lead sponsor
- VA Office of Research and DevelopmentFederal agency
- Sponsor type
- Federal agency
- First posted
- Aug 13, 2014
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goals of this project are 1) to assess the effectiveness and cost-effectiveness of the checklist to prevent MRSA SSIs among Veterans undergoing TJA or cardiac surgery, and 2) to assess barriers and facilitators to checklist implementation. Hypotheses: 1. The SSI checklist will be effective at reducing MRSA SSIs among total joint arthroplasty and cardiac surgery patients. 2. Implementation of the checklist will be associated with an overall reduction in SSIs caused by all pathogens. 3. The SSI Checklist will be cost-saving since it will prevent many expensive SSIs. 4. Preoperative MRSA testing will be a modifiable barrier to implementing the SSI checklist.
Conditions
- Surgical Site Infection
Interventions
MupirocinDrug
Patients with known positive MRSA or MSSA and patients who have unknown status will decolonize BID x 5 days
Chlorhexidine gluconateDrug
Patients that are MRSA or MSSA positive or have unknown status will bathe in CHG daily x 5 days. Patients that are MRSA or MSSA negative will bathe with CHG the night before and morning of surgery.
CefazolinDrug
All patients will receive Cefazolin during surgery
VancomycinDrug
Patients who are positive for MRSA, or have unknown MRSA status, will receive vancomycin along with cefazolin during surgery.
Nasal Povidone IodineDrug
The purpose of this research is to evaluate a SSI checklist. This checklist includes decolonizing a patient's nose and skin and optimizing antibiotics prior to surgery. At the time that we wrote it, the predominate product to decolonize patient's noses was mupirocin. However, in 2017, an FDA final monograph stated that nasal povidone-iodine may be used for pre-surgical decolonization. Nasal povidone-iodine should be able to overcome barriers to checklist implementation that we identified in Aim 3. We now plan to replace the nasal agent mupirocin with the nasal agent povidone-iodine at 3 participating medical centers (Iowa City VA, Minneapolis VA and Portland VA) to assess whether this overcomes the barriers to our SSI checklist.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Participants With Superficial and Deep/Organ Space MRSA Infections Within 90 DaysTime frame: 90 days postoperatively
Locations
11 sites in 1 country. Site status is shown where the registry gives one.
Miami VA Healthcare System, Miami, FL
Miami, Florida
Iowa City VA Health Care System, Iowa City, IA
Iowa City, Iowa
Baltimore VA Medical Center VA Maryland Health Care System, Baltimore, MD
Baltimore, Maryland
VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA
Boston, Massachusetts
VA Ann Arbor Healthcare System, Ann Arbor, MI
Ann Arbor, Michigan
Minneapolis VA Health Care System, Minneapolis, MN
Minneapolis, Minnesota
Omaha VA Nebraska-Western Iowa Health Care System, Omaha, NE
Omaha, Nebraska
VA Portland Health Care System, Portland, OR
Portland, Oregon
South Texas Health Care System, San Antonio, TX
San Antonio, Texas
VA Salt Lake City Health Care System, Salt Lake City, UT
Salt Lake City, Utah
William S. Middleton Memorial Veterans Hospital, Madison, WI
Madison, Wisconsin
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.